Drug Trial Radar · NCT06741397
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
229
Actual
Start
Dec 20, 2024
Primary completion
Sep 9, 2026
Study completion Aug 30, 2029
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the pharmacokinetics (PK), safety, and tolerability of a new formulation of Cabotegravir (CAB) dosed every 4-months (Q4M) for pre-exposure prophylaxis (PrEP) in participants at risk of HIV-1 acquisition.
Conditions
- HIV Infections
Interventions
CAB LADrug
Injections administered IM gluteal.
New formulation of CAB LADrug
Injections administered IM gluteal.
Primary outcomes
What the sponsor says the trial is designed to measure.
- CAB trough concentrations for target of 1.05 microgram per milliliter (μg/mL) for men and 1.39 μg/mL for womenTime frame: From Month 13 to Month 25
Locations
27 sites in 2 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Birmingham, Alabama
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Palm Springs, California
GSK Investigational Site
Doral, Florida
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
West Palm Beach, Florida
GSK Investigational Site
Chicago, Illinois
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Springfield, Massachusetts
GSK Investigational Site
Berkley, Michigan
GSK Investigational Site
Kansas City, Missouri
GSK Investigational Site
Las Vegas, Nevada
GSK Investigational Site
Hawthorne, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
Greensboro, North Carolina
GSK Investigational Site
Cincinnati, Ohio
GSK Investigational Site
Columbus, Ohio
GSK Investigational Site
Pittsburgh, Pennsylvania
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Fort Worth, Texas
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
San Juan, Puerto Rico
GSK Investigational Site
San Juan, Puerto Rico
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.